期刊文献+

非甾体类孕酮受体激动剂Tanaproget对兔动脉硬化的抑制作用及其机制 被引量:2

下载PDF
导出
摘要 目的探讨非甾体类孕酮受体激动剂Tanaproget对动脉硬化的影响及其可能的机制。方法健康新西兰大白兔24只随机分为正常饲料(干草粉)喂养组(正常组)、高脂饲料(2%胆固醇+1%猪油+90%普通饲料)喂养组(模型组)、高脂饲料加Tanaproget喂养组(干预组),模型组及干预组于喂养第1周末,耳缘静脉注射牛血清白蛋白250 mg/kg。实验1周末和10周末,检测血清甘油三脂(TG)、低密度脂蛋白胆固醇(LDL-C),ELISA法检测血清白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α);实验10周末随机抽取每组中一只取主动脉做油红O染色,其余取主动脉弓做石蜡包埋切片并行HE染色,提取血管组织蛋白,采用Western blotting法检测核转录因子κB(NF-κB)和Toll样受体4(TLR4)。结果实验10周末模型组和干预组血清TG、LDL-C水平较正常组升高(P均<0.01);实验后模型组血清IL-8、TNF-α水平较正常组和干预组升高(P均<0.01);大体标本油红O染色肉眼可见模型组斑块明显多于、大于正常组和干预组;HE染色后模型组主动脉内膜厚度明显大于正常组和干预组。模型组NF-κB、TLR4表达明显高于正常组和干预组(P均<0.01)。结论 Tanaproget通过特异性与孕酮受体结合后调节血脂代谢,同时抑制活化的TLR4/NF-κB信号通路,减少炎症因子的转录与生成,从而发挥其抗动脉硬化作用。
出处 《山东医药》 CAS 北大核心 2016年第17期34-36,共3页 Shandong Medical Journal
  • 相关文献

参考文献9

  • 1李琳,窦健霖,楚天舒,李婉秋,张戈,孙林.高脂饲料喂养加静脉注射小牛血清白蛋白建立兔动脉粥样硬化模型[J].中国组织工程研究,2012,16(20):3690-3693. 被引量:27
  • 2吕占清,谷菲.超敏C反应蛋白联合血脂检测对诊断冠状动脉硬化的意义[J].中国社区医师,2015,31(17):106-106. 被引量:2
  • 3Goddard LM,Ton AN,Qrq T,et al.Selective suppression of endothelial cytokine production by progesterone receptor[J].Vasc Pharmacol,2013,59(1-2):36-43.
  • 4Yan ZQ.Regulation of TLR4 expression is a tale about tail[J].Arterioscle Thromb Vasc Biol,2006,26(12):2582-2584.
  • 5Zhang Z,Olland AM,Zhu Y,et al.Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptoragonist tanaproget[J].J Biol Chem,2005,280(31):28468-28475.
  • 6李桂源.病理生理学[M].北京:人民卫生出版社,2005.236-240.
  • 7Grandas OH,Mountain DJ,Kirkpatrick SS,et al.Effect of hormones on matrix metalloproteinases gene regulation in human aortic smooth muscle cells[J].J Surg Res,2008,148(1):94-99.
  • 8Bruner-Tran KL,Zhang Z,Eisenberg E,et al.Down-regulation of endometrial matrix metalloproteinase-3 and-7 expression in vitro and therapeutic regressionof experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist,tanaproget[J].J Clin Endocrinel Metab,2006,91(4):1554-1560.
  • 9胡平,任梦鹤,童彩霞,吕子敏.非甾体类孕酮受体配体构效关系的研究进展[J].中国新药杂志,2008,17(11):905-910. 被引量:3

二级参考文献39

  • 1顾晴,陈纪林,阮英茆.阿司匹林、氯吡格雷及合用对兔动脉粥样硬化病变进展的抑制作用[J].中国医学科学院学报,2005,27(1):87-91. 被引量:46
  • 2SHINEI R, KURIHARA K, TANABE K, et al. Nonsteroidal progesterone receptor ligands (Ⅰ) : synthesis and SAR of new tetrahydronaphthofuranone derivatives [ J ]. Bioorg Med Chem,2006, 14(14) :4850 -4861.
  • 3KURIHARA K, SHINEI R, TANABE K, et al. Nonsteroidal progesterone receptor ligands (Ⅱ) : synthesis and SAR of new tetrahydrobenzindolone derivatives [ J ]. Bioorg Med Chem,2006,14 (14) :4862 -4878.
  • 4TABATA Y, IIZUKA Y, SHINEI R, et al. CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton [ J ]. Eur J Pharmacol, 2003,461 (1) :73 -78.
  • 5DONG Y, ROBERGE JY, WANG Z, et al. Characterization of a new class of selective nonsteroidal progesterone receptor agonists [ J ]. Steroids,2004,69 ( 3 ) : 201 - 217.
  • 6CONNOLLY PJ, WETTER SK, BEERS KN, et al. Synthesis and progesterone receptor binding affinity of substituted 1-phenyl- 7-benzyl-4,5,6, 7-tetrahydro-1 H- indazoles [ J ]. Bioorg Med Chem Lett,1997,7(19) :2551 -2556.
  • 7PALMER S, CAMPEN CA, ALLAN GF, et al. Nonsteroidal progesterone receptor ligands with unprecedented receptor selectivity [ J ]. J Steroid Biochem Mol Biol, 2000,75 ( 1 ) : 33 - 42.
  • 8ZHI L, TEGLEY CM, EDWARDS JP, et al. 5-alkyl 1,2-dihydrochromeno[ 3,4-f] quinolines: A novel class of nonsteroidal progesterone receptor modulators [ J ]. Bioorg Med Chem Lett, 1998,8 (23) :3365 - 3370
  • 9ZHI L, TEGLEY CM, PIO B, et al. Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno [ 3,4-f] quinoline derivatives as progesterone receptor modulators [ J]. Bioorg Med Chem Lett,2003,13 ( 12 ) : 2071 - 2074.
  • 10ZHI L, RINGGENBERG JD, EDWARDS JP, et al. Development of progesterone receptor antagonists from 1,2-dihydroehromeno [ 3,4-f] quinoline agonist pharmaeophore [ J ]. Bioorg Med Chem Lett,2003, 13(12) :2075 -2078.

共引文献31

同被引文献27

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部